J 2018

Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients

POPRACH, Alexandr, Ondrej FIALA, Renata CHLOUPKOVÁ, Bohuslav MELICHAR, Radek LAKOMÝ et. al.

Basic information

Original name

Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients

Authors

POPRACH, Alexandr (203 Czech Republic, guarantor, belonging to the institution), Ondrej FIALA (203 Czech Republic), Renata CHLOUPKOVÁ (203 Czech Republic, belonging to the institution), Bohuslav MELICHAR (203 Czech Republic), Radek LAKOMÝ (203 Czech Republic, belonging to the institution), Katarína PETRÁKOVÁ (203 Czech Republic, belonging to the institution), Milada ZEMANOVA (203 Czech Republic), Katerina KOPECKOVA (203 Czech Republic), Ondřej SLABÝ (203 Czech Republic, belonging to the institution), Hana STUDENTOVA (203 Czech Republic), Jindrich KOPECKY (203 Czech Republic), Igor KISS (203 Czech Republic, belonging to the institution), Jindrich FINEK (203 Czech Republic), Ladislav DUŠEK (203 Czech Republic) and Tomas BUCHLER (203 Czech Republic)

Edition

Anticancer Research, Athens, The International Institute of Anticancer Research, 2018, 0250-7005

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Greece

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 1.935

RIV identification code

RIV/00216224:14110/18:00102719

Organization unit

Faculty of Medicine

UT WoS

000419130100060

Keywords in English

Renal cell carcinoma; pazopanib; response; survival; cancer registry

Tags

International impact, Reviewed
Změněno: 26/4/2021 13:46, Mgr. Tereza Miškechová

Abstract

V originále

Background: Pazopanib is approved for the first-line treatment of patients with metastatic renal cell carcinoma (mRCC). The present study was a retrospective registry-based analysis of 426 patients with mRCC treated with pazopanib as first-line targeted therapy. Patients and Methods: The data were obtained from the Renal Cell Carcinoma Information system registry. Patient baseline parameters, treatment course and outcomes, and toxicity were analysed. Results: Median progression-free and overall survival were 12.9 (95% confidence interval(CI)=11.0-14.8) months and 33.2 (95% CI=29.9-36.4) months, respectively. Overall response rate and disease control rate were 25.1% and 57.4%, respectively. Adverse events led to discontinuation of treatment in 37 (12.1%) patients. Conclusion: The results confirm that pazopanib is an effective and safe first-line targeted treatment in patients with mRCC. Both the International mRCC Database Consortium and the Memorial Sloan Kettering models were valid predictors of prognosis and nephrectomy was associated with improved survival.

Links

ED1.1.00/02.0068, research and development project
Name: CEITEC - central european institute of technology
NT13547, research and development project
Name: Studium mikroRNA a genů asociovaných s procesem epiteliálně-mezenchymální tranzice jako potenciálních markerů pro predikci rizika a časný záchyt metastazování u pacientů s renálním karcinomem
NV15-34678A, research and development project
Name: Molekulární prognostické a prediktivní faktory u pacientů s metastatickým renálním karcinomem léčených tyrozinkinázovými inhibitory
90004, large research infrastructures
Name: BBMRI-CZ